Insulin– tag –
-
Dexcom Secures FDA Authorization for Stelo Glucose Biosensor System, First OTC CGM for Non-Diabetic and Non-Insulin Using Individuals
Devices@FDA (Dexcom) USA Overview Dexcom, Inc. has received FDA authorization for its 'Stelo Glucose Biosensor System,' marking it as the first over-the-counter (OTC) integrated continuous glucose monitor (iCGM) specifically for individu... -
HealthPartners Launches Program Expanding CGM Access and Integrating Pharmacist Support for Insulin-Treated Diabetics
Morningstar (HealthPartners) USA Overview HealthPartners has initiated a new quality improvement program aimed at expanding access to continuous glucose monitoring (CGM) technology and providing personalized support for diabetic patients... -
Abbott Receives FDA Authorization for Libre Duo 10 Day: World’s First Dual Continuous Glucose and Ketone Monitoring System for Early DKA Warning
Medical Update Online (Abbott) USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day, the world's first dual continuous glucose and ketone monitoring (CGKM) system. This novel bio-wearable provides real-time glucose ... -
Future of Continuous Glucose Monitoring: IDF Europe Advocates User-Centric Approach for Technology Selection in 2026
IDF Europe Belgium Overview IDF Europe has released an expert opinion asserting that Continuous Glucose Monitoring (CGM) has become an indispensable tool transforming diabetes management and supporting personalized care by 2026. Newer ge... -
Vertex Pharmaceuticals Initiates Phase I/II for Type 1 Diabetes Cell Therapy, Expands Renal Pipeline at Morgan Stanley Conference
MarketBeat USA Overview Vertex Pharmaceuticals unveiled its ambitious growth strategy beyond cystic fibrosis at the Morgan Stanley 24th Global Healthcare Conference, emphasizing its renal pipeline and a groundbreaking cell therapy progra... -
Five Key Trends in Diabetes Technology for 2026: Longer-Lasting CGMs, OTC Expansion, and Multi-Biomarker Monitoring Lead Innovation
DiabeticSupplieInc.com Unknown Overview Five major trends are shaping diabetes technology in 2026, including longer-lasting continuous glucose monitoring (CGM) sensors like the FDA-cleared Dexcom G7 15-day system, expanded CGM access for... -
FDA Approves Dexcom’s Stelo System as First Over-the-Counter Continuous Glucose Monitor for Children Ages 2-18
RadioWHAT (Facebook) USA Overview The FDA has approved Dexcom's Stelo system as the first over-the-counter (OTC) continuous glucose monitor (CGM) available for children aged 2 to 18 without a prescription. This device provides 15-minute ... -
Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes
TipRanks / Sana Biotechnology, Inc. USA Overview Sana Biotechnology updated its investor presentation, emphasizing pipeline advancements, particularly for SC451, an iPSC-derived hypoimmune pancreatic islet cell therapy for Type 1 diabete... -
Dexcom Gains FDA Clearance for G7 15-Day CGM and Smart Basal, Joins TEMPO Pilot Program
Simply Wall St USA Overview Dexcom has secured FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring (CGM) system, extending wear time to 15.5 days for all types of adult diabetes patients. Simultaneously, Dexcom Smart Bas... -
Abbott’s Libre Duo 10 Day System Receives FDA De Novo Clearance as First Integrated Continuous Glucose-Ketone Monitor
Pharmacy Times USA Overview Abbott's Libre Duo 10 Day system has received FDA De Novo clearance, becoming the first integrated continuous glucose-ketone monitoring (iCGK) system in the U.S. and the world's first wearable device to track ...
